Cybin (OTCMKTS:CYBN) Stock Price Down 2%

Cybin Inc. (OTCMKTS:CYBN - Get Free Report)'s share price fell 2% during mid-day trading on Thursday . The stock traded as low as $0.36 and last traded at $0.37. 1,714,145 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 5,246,800 shares. The stock had previously closed at $0.38.

Cybin Price Performance

The stock's 50 day simple moving average is $0.39 and its two-hundred day simple moving average is $0.43. The stock has a market cap of $149.96 million, a price-to-earnings ratio of -1.74 and a beta of 0.43.

Cybin (OTCMKTS:CYBN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.04). As a group, analysts predict that Cybin Inc. will post -0.19 earnings per share for the current year.

Institutional Investors Weigh In On Cybin

Several institutional investors and hedge funds have recently made changes to their positions in CYBN. Moneta Group Investment Advisors LLC raised its holdings in shares of Cybin by 133,816.7% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 66,405,251 shares of the company's stock valued at $19,729,000 after buying an additional 66,355,664 shares during the last quarter. Penserra Capital Management LLC raised its holdings in shares of Cybin by 55.8% in the first quarter. Penserra Capital Management LLC now owns 407,309 shares of the company's stock valued at $223,000 after buying an additional 145,929 shares during the last quarter. Royal Bank of Canada raised its holdings in shares of Cybin by 926.4% in the third quarter. Royal Bank of Canada now owns 109,239 shares of the company's stock valued at $52,000 after buying an additional 98,596 shares during the last quarter. Jane Street Group LLC raised its holdings in shares of Cybin by 370.6% in the first quarter. Jane Street Group LLC now owns 74,631 shares of the company's stock valued at $61,000 after buying an additional 58,771 shares during the last quarter. Finally, Belpointe Asset Management LLC raised its holdings in shares of Cybin by 21.5% in the first quarter. Belpointe Asset Management LLC now owns 313,705 shares of the company's stock valued at $121,000 after buying an additional 55,600 shares during the last quarter. Institutional investors and hedge funds own 17.94% of the company's stock.

Cybin Company Profile

Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.